Binds A Hematopoietic Cell Or Component Or Product Thereof (e.g., Erythrocyte, Granulocyte, Macrophage, Monocyte, Platelet, Myelogenous Leukemia Cell, Bone Marrow Stem Cell, Granulocytic Cell Surface Antigen, Hemoglobin, Thrombospondin, Glycophorin, Etc.) Patents (Class 435/343)
  • Patent number: 11407991
    Abstract: Methods for extracting high quality nucleic acids from a heterogenous collection of nucleic acid-containing materials from a biological sample are disclosed. The heterogenous collection of nucleic-acid containing materials may contain cells or microvesicles, or both. The extractions obtained by the methods described herein are characterized by high yield and high integrity, making the extracted nucleic acids useful for various applications in which high quality nucleic acid extractions are preferred, e.g., a diagnosis, prognosis, or therapy evaluation for a medical condition.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 9, 2022
    Assignee: Exosome Diagnostics, Inc.
    Inventors: Wayne Comper, Leileata M. Russo, Johan Karl Olov Skog
  • Patent number: 11104718
    Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bayer HealthCare LLC
    Inventors: Alan Brooks, Richard Feldman, Jian-Ming Gu, Shaun Lippow, Shujun Yuan, Peter Bringmann
  • Patent number: 8981072
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 17, 2015
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8957193
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 17, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20140322235
    Abstract: The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.
    Type: Application
    Filed: December 14, 2011
    Publication date: October 30, 2014
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), INSTITUT PAOLI-CALMETTES, UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille II
    Inventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
  • Patent number: 8865479
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: October 21, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835187
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835188
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Patent number: 8772049
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 8, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Publication number: 20140162357
    Abstract: This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner.
    Type: Application
    Filed: September 4, 2013
    Publication date: June 12, 2014
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Yosef Refaeli, Brian C. Turner
  • Publication number: 20140065146
    Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
    Type: Application
    Filed: September 30, 2013
    Publication date: March 6, 2014
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
  • Publication number: 20140004037
    Abstract: The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.
    Type: Application
    Filed: January 19, 2012
    Publication date: January 2, 2014
    Applicant: Therapeutic Proteins, Inc.
    Inventor: Rosemarie Wilton
  • Patent number: 8546331
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: October 1, 2013
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Publication number: 20130230540
    Abstract: The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain.
    Type: Application
    Filed: July 10, 2012
    Publication date: September 5, 2013
    Applicant: Domantis Limited
    Inventors: Steven Holmes, Carrie Enever, Steven Grant, David Sansom
  • Patent number: 8481313
    Abstract: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: July 9, 2013
    Assignee: Regenerative Research Foundation
    Inventors: Sally Temple, Jeffrey Stern, Enrique L. Salero-Coca
  • Patent number: 8404241
    Abstract: The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: March 26, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Christine Gaucher, Sylvie Jorieux, Christophe De Romeuf
  • Patent number: 8361468
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: January 29, 2013
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Patent number: 8323652
    Abstract: This application relates to agents capable of specifically recognizing GPIb?, a key receptor required for platelet adhesion and aggregation. More specifically, this application relates to monoclonal antibodies and derivatives thereof capable of specifically recognizing both the murine and the human GPIb?. These monoclonal antibodies and derivatives are particularly useful in the treatment or prevention of thrombosis as well as research tools.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: December 4, 2012
    Assignee: Canadian Blood Services
    Inventors: Heyu Ni, Guangheng Zhu
  • Patent number: 8287853
    Abstract: Stem cells obtained through in vitro culture with heparan sulphate are described.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: October 16, 2012
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon McKenzie Cool, Victor Nurcombe
  • Patent number: 8242074
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: August 14, 2012
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Publication number: 20120135003
    Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.
    Type: Application
    Filed: November 22, 2011
    Publication date: May 31, 2012
    Applicant: SBI Biotech, Ltd.
    Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
  • Patent number: 8178085
    Abstract: The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: May 15, 2012
    Assignee: Agency for Science, Technology and Research
    Inventors: Victor Nurcombe, Simon Cool
  • Publication number: 20120027769
    Abstract: Anti-RhD monoclonal antibodies and methods for the production thereof.
    Type: Application
    Filed: December 24, 2009
    Publication date: February 2, 2012
    Inventors: Gautam Vinod Daftary, John Kaundinya, Tomas Cinek
  • Patent number: 8048855
    Abstract: A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD can be suppressed by administering human G-CSF to a transplantation recipient after peripheral blood stem cells transplantation.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 1, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Motoyuki Kataoka, Kaname Yamamoto
  • Publication number: 20110217695
    Abstract: The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.
    Type: Application
    Filed: November 12, 2009
    Publication date: September 8, 2011
    Applicant: Schering Corporation
    Inventor: Deba P. Saha
  • Patent number: 8008073
    Abstract: Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: August 30, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Tsunoda, Kiyotaka Nakano, Tetsuro Orita, Masayuki Tsuchiya, Yuichi Hirata
  • Patent number: 7915004
    Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: March 29, 2011
    Assignee: Farma Development S.r.l.
    Inventors: Alberto Mantovani, Giuseppe Peri
  • Patent number: 7915041
    Abstract: A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: March 29, 2011
    Assignee: Seikagaku Corporation
    Inventors: Yoshiyuki Adachi, Naohito Ohno
  • Publication number: 20110039300
    Abstract: The present invention concerns antibodies with enhanced antibody-dependent cell mediated cytotoxicity (ADCC) and method for preparation thereof.
    Type: Application
    Filed: August 6, 2010
    Publication date: February 17, 2011
    Inventors: ROBERT BAYER, Amy Shen, Reed J. Harris, Domingos Ng
  • Patent number: 7842513
    Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: November 30, 2010
    Assignees: AspenBio Pharma, Inc., University of Wyoming
    Inventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin
  • Patent number: 7829092
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: November 9, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Patent number: 7820807
    Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 26, 2010
    Assignee: Pangenetics BV
    Inventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simons
  • Patent number: 7816500
    Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 19, 2010
    Inventor: Robert Sackstein
  • Patent number: 7795018
    Abstract: The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: September 14, 2010
    Assignee: Keio University
    Inventors: Masataka Kuwana, Hiroaki Kodama
  • Patent number: 7790166
    Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: September 7, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mark de Boer, Leah B. Conroy
  • Patent number: 7754867
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: July 13, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Patent number: 7741114
    Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on 14 Aug. 2002, and DSM ACC2551, on 12 Jul. 2002.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: June 22, 2010
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Hans-Joerg Buehring, Reiner Lammers, Selim Kuci, Tim Conze
  • Patent number: 7731966
    Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: June 8, 2010
    Assignee: Canadian Blood Services
    Inventors: Heyu Ni, Guangheng Zhu
  • Patent number: 7718780
    Abstract: The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: May 18, 2010
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Eun Young Song, Jae Wha Kim, Hee Gu Lee, Jong Seok Lim, Seung Chul Choi, Mi Young Cho, Kyoung Eun Baek, Jin Sook Kim, Jong Tae Kim, Do Young Yoon, Dur Han Kwon, Mi-Young Park, Young Il Yeom, Yong-Kyung Choe, Young-Jun Kim
  • Patent number: 7714107
    Abstract: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 11, 2010
    Assignee: ProChon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Patent number: 7708977
    Abstract: A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: May 4, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toren Finkel, Jonathan M. Hill, Arshed A. Quyyumi
  • Patent number: 7626012
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: December 1, 2009
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
  • Patent number: 7618633
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: November 17, 2009
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
  • Patent number: 7576188
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: August 18, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, José Jimeno, Glynn Thomas Faircloth
  • Patent number: 7547438
    Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: June 16, 2009
    Assignee: Pangenetics BV
    Inventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simone
  • Patent number: 7537763
    Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: May 26, 2009
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Toshifumi Mikayama, Hitoshi Yoshida, Walker R. Force, Xingjie Chen, Nobuaki Takahashi
  • Patent number: 7445780
    Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: November 4, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Keting Chu, Lorianne K. Masuoka
  • Patent number: 7361345
    Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
    Type: Grant
    Filed: February 7, 2005
    Date of Patent: April 22, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mark de Boer, Leah B. Conroy
  • Patent number: RE44359
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: July 9, 2013
    Assignee: Hoffmann-La Roche Inc
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt